|
|
|
|
|||||
|
|
|
PLYMOUTH MEETING, Pa., March 9, 2026 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced that it will participate in the following scientific conferences:
Eurogin HPV Conference (Vienna, Austria)
Date: Thursday, March 19
Time: 8:00 AM CET
Presentation: DNA Immunotherapy INO-3107 Demonstrates Long-Term Surgical Intervention Reduction in HPV-6 & 11 RRP
World Vaccine Congress DC (Washington, DC)
Date: Monday, March 30
Time: 11:50 AM ET
Presentation: Novel DNA-Encoded Monoclonal Antibody Technology: Durable and Tolerable In Vivo Expression of mAbs Targeting COVID
Available abstracts will be shared on INOVIO's website following presentations.
About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.
Contacts
Media: Jennie Willson, (267) 429-8567, [email protected]
Investors: Peter Vozzo, ICR Healthcare, (443) 213-0505, [email protected]
SOURCE INOVIO Pharmaceuticals, Inc.
| Mar-09 | |
| Mar-05 | |
| Mar-04 | |
| Mar-04 | |
| Feb-26 | |
| Feb-25 | |
| Feb-20 | |
| Feb-12 | |
| Feb-12 | |
| Dec-30 | |
| Dec-29 | |
| Dec-19 | |
| Nov-18 | |
| Nov-14 | |
| Nov-11 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about Finviz Elite